Adjunctive dabigatran therapy improves outcome of experimental left-sided Staphylococcus aureus endocarditis.
Christian J Lerche, Lars J Christophersen, Jens Peter Goetze...
https://pubmed.ncbi.nlm.nih.gov/31002679/Actively Recruiting
Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2026-09-24
300
Participants Needed
3
Research Sites
N/A
Total Duration
Researchers are evaluating whether switching to dabigatran improves outcomes for patients with Staphylococcus aureus bacteremia who are already taking oral anticoagulants called anti-Xa inhibitors apixaban, edoxaban, or rivaroxaban. Dabigatran is approved for similar uses and shows activity against S. aureus in laboratory and animal studies, as well as in a smaller trial. This trial is a sub-study within a larger Staphylococcus aureus Network Adaptive Platform SNAP trial. Participants are randomly assigned to continue their current anti-Xa inhibitor or switch to dabigatran at a dose approved for their condition, bleeding risk, and kidney function. The study compares these two approaches to see if dabigatran offers better results. The treatment period aligns with their clinical indication, and dosing is personalized based on individual factors. During the trial, participants will be monitored for clinical outcomes including safety events, treatment failure, and mortality, assessed 90 days after enrollment in the SNAP trial. Researchers will track serious adverse events, bleeding, blood clots, strokes, and heart-related events. Participants remain under medical supervision throughout, and study results will inform future research on anticoagulation in this infection setting.
CONDITIONS
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
F
Fatima Amari
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
University of Melbourne
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 90 days
Participants are randomly assigned to either switch their anticoagulant medication to dabigatran or continue their current oral anti-Xa inhibitor. Dosing is personalized based on medical condition, bleeding risk, and kidney function.
Regular monitoring visits as part of the SNAP trial
Duration - At 90 days post enrollment
Researchers assess clinical outcomes including treatment success, adverse events, bleeding, blood clots, stroke, and mortality 90 days after enrollment.
1 assessment visit
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Christian J Lerche, Lars J Christophersen, Jens Peter Goetze...
https://pubmed.ncbi.nlm.nih.gov/31002679/Emily G McDonald, Matthew P Cheng, Joshua S Davis...
https://pubmed.ncbi.nlm.nih.gov/41387009/Marijke Peetermans, Laurens Liesenborghs, Kathelijne Peerlinck...
https://pubmed.ncbi.nlm.nih.gov/29614521/Thomas Vanassche, Jan Verhaegen, Willy E Peetermans...
https://pubmed.ncbi.nlm.nih.gov/20810780/Steven Y C Tong, Jocelyn Mora, Asha C Bowen...
https://pubmed.ncbi.nlm.nih.gov/35717634/Jawad H Butt, Emil L Fosbøl, Peter Verhamme...
https://pubmed.ncbi.nlm.nih.gov/32478836/T Vanassche, J Verhaegen, W E Peetermans...
https://pubmed.ncbi.nlm.nih.gov/22040101/McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
University of Melbourne
Collaborating Sponsor